A Pilot Trial of Cognitive-Behavioral Therapy Augmentation of Antibiotic Treatment in Youth with Pediatric Acute-Onset Neuropsychiatric Syndrome-Related Obsessive-Compulsive Disorder
Restricted accessResearch articleFirst published online May, 2015
A Pilot Trial of Cognitive-Behavioral Therapy Augmentation of Antibiotic Treatment in Youth with Pediatric Acute-Onset Neuropsychiatric Syndrome-Related Obsessive-Compulsive Disorder
This study reports an open trial of family-based cognitive-behavioral therapy (CBT) in children and adolescents with obsessive-compulsive disorder (OCD) exhibiting an onset pattern consistent with pediatric acute-onset neuropsychiatric syndrome (PANS).
Methods:
Eleven primarily Caucasian youth with PANS-related OCD (range=4–14 years; 6 boys) who were incomplete responders to antibiotic treatment, received family-based CBT delivered either face-to-face or via web camera.
Results:
All participants completing treatment (8 of 8) were considered improved at posttreatment, and average obsessive-compulsive symptom severity was reduced by 49%. Significant reductions in obsessive-compulsive symptom severity and in clinician- and parent-rated OCD-related impairment were noted. Reductions in parent- and child-rated anxiety, child-rated OCD-related impairment, and comorbid neuropsychiatric symptoms were not statistically significant.
Conclusions:
Gains were maintained at follow-up, with 100% (6 of 6) of those assessed remaining improved. Implications for treatment and further research are discussed.
Get full access to this article
View all access options for this article.
References
1.
AbramowitzJS, WhitesideSP, DeaconBJ: The effectiveness of treatment for pediatric obsessive-compulsive disorder: A meta-analysis. Behav Ther, 36:55–63, 2005.
2.
AchenbachTM, RescorlaL: Manual for the Achenbach System of Empirically Based Assessment (ASEBA) School-Age Forms and Profiles. Burlington, VT: ASEBA; 2001.
3.
AllenAJ, LeonardHL, SwedoSE: Case study: A new infection-triggered, autoimmune subtype of pediatric OCD and Tourette's syndrome. J Am Acad Child Adolesc Psychiatry, 34:307–311, 1995.
4.
ArbuckleJL: Full Information Estimation in the Presence of Incomplete Data. Mahwah, NJ: Erlbaum; 1996.
BirmaherB, KhetarpalS, BrentD, CullyM, BalachL, KaufmanJ, NeerSM: The screen for child anxiety related emotional disorders: scale construction and psychometric characteristics. J Am Acad Child Adolesc Psychiatry, 36:545–553, 1997.
7.
CohenJ: Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Hillsdale, NJ: Erlbaum; 1988.
8.
GarveyMA, PerlmutterSJ, AllenAJ, HamburgerS, LougeeL, LeonardHL, WitowskiME, DubbertB, SwedoSE: A pilot study of penicillin prophylaxis for neuropsychiatric exacerbations triggered by streptococcal infections. Biol Psychiatry, 45:1564–1571, 1999.
9.
GoodmanWK, PriceLH, RasmussenSA, MazureC, FleischmannRL, HillCL, HenningerGR, CharneyDS: The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. Arch Gen Psychiatry, 46:1006–1011, 1989.
10.
GuyW: ECDEU Assessment Manual for Psychopharmacology–Revised. Volume Department of Health, Education, and Welfare Publ. No. ADM 76 338. Rockville, MD. U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, pp 218–222, 1976.
11.
LeckmanJF, SholomaskasD, ThompsonWE, BelangerA, WeissmanMM: Best estimate of lifetime psychiatric diagnosis: A methodological study. Arch Gen Psychiatry, 39:879–883, 1982.
12.
LewinAB, PiacentiniJ: Evidence-based assessment of child obsessive compulsive disorder: Recommendations for clinical practice and treatment research. Child & Youth Care Forum. 39:73–89, 2010.
MurphyTK, KurlanR, LeckmanJ: The immunobiology of Tourette's disorder, pediatric autoimmune neuropsychiatric disorders associated with Streptococcus, and related disorders: A way forward. J Child Adolesc Psychopharmacol, 20:317–331, 2010.
16.
MurphyTK, Parker–AthillEC, LewinAB, StorchEA, MutchPJ: Cefdinir for recent onset pediatric neuropsychiatric disorders: A pilot randomized trial. J Child Adolesc Psychopharmacol, 25:57–64, 2015a.
MurphyML, PichicheroME: Prospective identification and treatment of children with pediatric autoimmune neuropsychiatric disorder associated with group A streptococcal infection (PANDAS). Arch Pediatr Adolesc Med, 156:356–361, 2002.
National Institute of Mental Health: Clinical Global Impressions Scale (CGI) Psychopharmacol. Bull, 21:747–748, 1985.
21.
Pediatric OCD Treatment Study Team: Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The Pediatric OCD Treatment Study (POTS) Randomized Controlled Trial. J Am Med Assoc, 292:1969–1976, 2004.
22.
PerlmutterSJ, LeitmanSF, GarveyMA, HamburgerS, FeldmanE, LeonardHL, SwedoSE: Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet, 354:1153–1158, 1999.
23.
PiacentiniJ, BergmanRL, ChangS, LangleyA, PerisT, WoodJJ, McCrackenJ: Controlled comparison of family cognitive behavioral therapy and psychoeducation/relaxation training for child obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry, 50:1149–1161, 2011.
24.
PiacentiniJC, JafferMP: Measuring Functional Impairment in Youngsters with OCD: Manual for the Child OCD Impact Scale (COIS). Los Angeles: UCLA Department of Psychiatry; 1999.
25.
RUPP Anxiety Study Group: Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med, 344:1279–1285, 2001.
SchlomerGL, BaumanS, CardNA: Best practices for missing data management in counseling psychology. J Couns Psychol, 57:1–10, 2010.
28.
ShafferD, GouldMS, BrasicJ, AmbrosiniP, FisherP, BirdH, AluwahliaS: A Children's Global Assessment Scale (CGAS). Arch Gen Psychiatry, 40:1228–1231, 1983.
29.
SilvermanWK, AlbanoAM: Anxiety Disorders Interview Schedule for DSM-IV: Parent Interview Schedule, Vol 1. New York: Oxford University Press; 1996.
30.
SniderLA, LougeeL, SlatteryM, GrantP, SwedoSE: Antibiotic prophylaxis with azithromycin or penicillin for childhood-onset neuropsychiatric disorders. Biol Psychiatry, 57:788–792, 2005.
31.
StorchEA, BussingR, SmallBJ, GeffkenGR, McNamaraJP, RahmanO, LewinAB, GarvanCS, GoodmanWK, MurphyTK: Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive–compulsive disorder. Behav Res Ther, 51:823–829, 2013.
32.
StorchEA, CaporinoNE, MorganJR, LewinAB, RojasA, BrauerL, LarsonMJ, MurphyTK: Preliminary investigation of web-camera delivered cognitive-behavioral therapy for youth with obsessive-compulsive disorder. Psychiatry Res, 189:407–412, 2011.
33.
StorchEA, GerdesA, AdkinsJ, GeffkenGR, StarJ, MurphyTK: Behavioral treatment of child with pediatric autoimmune neuropsychiatric disorder associated with group A streptococcal infection. J Am Acad Child Adolesc Psychiatry, 43:510–511, 2004a.
34.
StorchEA, MurphyTK, GeffkenGR, MannG, AdkinsJ, MerloLJ, DukeD, MunsonM, SwaineZ, GoodmanWK: Cognitive-behavioral therapy for PANDAS-related obsessive-compulsive disorder: Findings from a preliminary waitlist controlled open trial. J Am Acad Child Adolesc Psychiatry, 45:1171–1178, 2006.
SwedoSE, LeckmanJF, RoseNR: From research subgroup to clinical syndrome: modifying the PANDAS criteria to describe PANS (pediatric acute-onset neuropsychiatric syndrome). Pediatr Ther, 2:2, 2012.
37.
SwedoSE, LeonardHL, GarveyM, MittlemanB, AllenAJ, PerlmutterS, DowS, ZamkoffJ, DubbertBK, LougeeL. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry, 155:264–271, 1998.
